Rubius Therapeutics Inc. (RUBY) Fundamentals

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
SHARE INFORMATION
Market Cap$ 78,023,297
Shares Outstanding90,357,032
Float33,393,544
Percent Float36.96%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -2.23
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions302
Institutional Holdings Date2022-06-30
Institutional Bought Previous 3 Months3,476,334
Institutional Holdings Percent45.3%
Institutional Sold Previous 3 Months10,205,656
Insider Holdings Date2022-05-31
Insider Bought Previous 3 Months674,762
Insider Holdings Percent7.7
Insider Sold Previous 3 Months-
Insider Shares Owned6,908,489
TRADING INFO
52 Week High$ 26.34
52 Week Low$ 0.75
52 Week High Change$ -96.67
21 Day Moving Average$ 0.9629
21 Day Extended Moving Average$ 0.990327
50 Day Moving Average$ 1.1842
50 Day Extended Moving Average$ 1.5971
200 Day Moving Average$ 7.9804
200 Day Extended Moving Average$ 6.969
10 Day Average Volume1,135,581
20 Day Average Volume1,256,431
30 Day Average Volume1,124,521
50 Day Average Volume1,359,259
Alpha-0.041927
Beta2.8218
Standard Deviation0.332254
R20.209089
7 Day Price Change$ -0.0991
7 Day Percent Change-10.3%
21 Day Price Change$ -0.095
21 Day Percent Change-9.91%
30 Day Price Change$ -0.0966
30 Day Percent Change-10.06%
Month to Date Price Change$ 0.0128
Month to Date Percent Change1.5%
Quarter to Date Price Change$ 0.0128
Quarter to Date Percent Change1.5%
180 Day Price Change$ -8.82
180 Day Percent Change-91.08%
200 Day Price Change$ -11.89
200 Day Percent Change-93.23%
Year to Date Price Change$ -8.82
Year to Date Percent Change-91.08%

Rubius Therapeutics Inc. (RUBY) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.60
Total Debt To Equity0.80
Int Coverage-31.70
Current Ratio6.20
Leverage Ratio1.90
Quick Ratio6.10
Long Term Debt To Capital0.43
VALUATION MEASURES
PE Ratio-0.40
Enterprise Value$ 14,043,297
Price to Sales0.00
Price to Free Cash-0.60
PE High Last 5 Years0.00
Price To Book0.60
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-61.37
Return on Equity-98.66
Return on Capital-60.34

Rubius Therapeutics Inc. (RUBY) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorPricewaterhouseCoopers LLP
CEOPablo J. Cagnoni
Emplyoees230
Last AuditUE
CIK0001709401
IndustryBiotechnology
SectorHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing(325414)
CONTACT INFO
Address399 Binney Street
Suite 300
Cambridge, MA 2139
Websitehttps://www.rubiustx.com
Facsimile-
Telephone+1 617 679-9600
Emaillori.melancon@rubiustx.com


Your Recent History
NASDAQ
RUBY
Rubius The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.